For the first-line treatment of patients with extensive stage small cell lung cancer (ES-SCLC) in combination with a platinum-based chemotherapy and etoposide. Maintenance TECENTRIQ should be continued until loss of clinical benefit or unacceptable toxicity
Notification to Implement Issued
Pre Noc Submission:
Hoffmann-La Roche Limited
Submission Deemed Complete:
Stakeholder Input Deadline ‡:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Do not reimburse
A procedural review request has been received and granted.
‡ Patient Advocacy Groups (or individual patients and caregivers
when there is no patient group) and Clinicians who are registered
with pCODR are eligible to provide Input and Feedback.
Deadlines for Input and Feedback are by the end of the pCODR business day
(5P.M. Eastern Time) of the date noted.